Projects

Search from 1171 projects:

Reset RSS

Time frame

Year

Year To

Project type

Project status

Unit

Recruitment

Labels

6 Project(s)

Apr 3, 2023

ScintiPOF: development of scintillation materials based on perovskitepolymer optical fiber composites for high-precision radiation oncology

Apr 3, 2023

Radiation Oncology today is more targeted, personalized, and deals with much smaller treatment regions. The small and highly sophisticated dose distributions pose great challenges for modern radiation dosimetry. High performance detectors are used to...

Fundamental Research - Apr 3, 2023 - Mar 28, 2025

Ongoing

Project leader: Buchauer Konrad

Aug 9, 2022

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Ac-cess

Aug 9, 2022

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support bio...

Clinical Studies - Aug 9, 2022 - Dec 31, 2027

Ongoing

Project leader: Appenzeller Christina
Members: Scherrer Julia, Quinter Janine

Mar 17, 2021

MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Mar 17, 2021

The rationale for this study comes from preclinical models, in which lenvatinib decreased the tumor-associated macrophage (TAM) population, which is known as an immune-regulator in the tumor microenvironment. The decrease in TAM population was accomp...

Clinical Studies - Mar 17, 2021 - May 7, 2030

Ongoing

Project leader: Fischer Stefanie
Members: Donno Monica, Quinter Janine

Mar 15, 2021

A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Mar 15, 2021

A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Clinical Studies - Mar 15, 2021 - Apr 7, 2030

Ongoing

Project leader: Silzle Tobias
Members: Driessen Christoph, Fehr Martin, Hitz Felicitas, Lehmann Thomas

Jan 1, 2021

Swiss Soliris® and Ultomiris® Reimbursement Registry SSURR: An observational registry for capturing data of patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) who are treated with Soliris® (eculizumab) or Ultomiris® (ravulizumab)

Jan 1, 2021

Clinical Studies - Jan 1, 2021 - Dec 31, 2030

Ongoing

Project leader: Silzle Tobias
Members: Demmer-Steingruber Ruth, Müller Fiona

Jul 24, 2019

SAKK 01/18 Reduced intensity radio-chemotherapy for satge IIA/B seminoma. A multicenter, open label phase II trial with 2 cohorts

Jul 24, 2019

Main objective: To investigate efficacy of a stage-adapted tratment regimen in stage IIA/B seminoma based on the preliminary experience gained in SAKK 01/10. The Goal is to further safely de-escalate Treatment while maintaining / enhancing efficacy.

Clinical Studies - Jul 24, 2019 - Jul 24, 2030

Ongoing

Project leader: Putora Paul Martin
Members: Plasswilm Ludwig, Rothermundt Christian, Patzl Sigrid, Fischer Stefanie